Compare PKE & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | BNTC |
|---|---|---|
| Founded | 1954 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.4M | 451.0M |
| IPO Year | N/A | N/A |
| Metric | PKE | BNTC |
|---|---|---|
| Price | $20.50 | $11.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.25 |
| AVG Volume (30 Days) | 83.1K | ★ 229.1K |
| Earning Date | 01-13-2026 | 11-14-2025 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 5.81 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $63,128,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.87 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $11.97 | $9.70 |
| 52 Week High | $21.52 | $17.15 |
| Indicator | PKE | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 38.63 |
| Support Level | $19.40 | $12.78 |
| Resistance Level | $21.20 | $13.68 |
| Average True Range (ATR) | 0.69 | 0.76 |
| MACD | 0.16 | 0.03 |
| Stochastic Oscillator | 74.01 | 22.20 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.